

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role  
NEWS 4 DEC 18 CA/CAplus patent kind codes updated  
NEWS 5 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000  
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 7 DEC 27 CA/CAplus enhanced with more pre-1907 records  
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 9 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded  
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 12 JAN 22 CA/CAplus updated with revised CAS roles  
NEWS 13 JAN 22 CA/CAplus enhanced with patent applications from India  
NEWS 14 JAN 29 PHAR reloaded with new search and display fields  
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 19 FEB 26 MEDLINE reloaded with enhancements  
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases  
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 25 MAR 16 CASREACT coverage extended  
NEWS 26 MAR 20 MARPAT now updated daily

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:27:21 ON 21 MAR 2007

=> file pctfull  
COST IN U.S. DOLLARS  
SINCE FILE  
ENTRY  
TOTAL  
SESSION  
0.21  
0.21  
FULL ESTIMATED COST

FILE 'PCTFULL' ENTERED AT 08:27:29 ON 21 MAR 2007  
COPYRIGHT (C) 2007 Univentio

FILE LAST UPDATED: 20 MAR 2007 <20070320/UP>  
MOST RECENT UPDATE WEEK: 200711 <200711/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s WO 200071135/pn  
L2 1 WO 200071135/PN  
      (WO200071135/PN)

```
=> s 12 and leukemia
    28368 LEUKEMIA
    8889 LEUKEMIAS
    30306 LEUKEMIA
                                (LEUKEMIA OR LEUKEMIAS)
L3          1 L2 AND LEUKEMIA
```

=> s 13 and lympho?  
56381 LYMPHO?  
I.4 1 I.3 AND LYMPHO?

⇒ d i b i b k w i c

L4 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2007 Univentio on STN  
ACCESSION NUMBER: 2000071135 PCTFULL ED 20020515  
TITLE (ENGLISH): ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS  
TITLE (FRENCH): AGENTS ANTI-TUMORALES CONTENANT DES COMPOSES DE  
BOROPROLINE  
INVENTOR(S): WALLNER, Barbara, P.;  
MILLER, Glenn  
PATENT ASSIGNEE(S): POINT THERAPEUTICS, INC.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

DESIGNATED STATES

W:

PRIORITY INFO.: US 1999-60/135,861 19990525

DETD . . . who have normal  
hernopoietic activity. In another embodiment, the subject is HIV  
negative. In certain  
embodiments, the subjects are not myeloid or lymphoid  
suppressed or are not candidates for  
treatment with an agent which causes such suppression at the time of  
treatment with the  
methods. . .

carcinoma, hypernephroid  
carcinoma, infantile embryonal carcinoma, carcinoma in situ,  
intraepidermal carcinoma,  
intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell  
carcinoma, lenticular  
carcinoma, carcinoma lenticulare, lipomatous carcinoma,  
lymphoepithelial carcinoma,  
carcinoma mastitoides, carcinoma medullare, medullary carcinoma,  
carcinoma melanodes,  
melanotic carcinoma, mucinous carcinoma, carcinoma muciparum, carcinoma  
mucocellulare,  
mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, . . .

As used herein, the terms hernopoietic and hematopoietic are used  
interchangeably to  
mean all blood cells including myeloid and lymphoid cells.  
Myeloid cells include  
erythrocytes (i.e., red blood cells), macrophages, monocytes,  
granulocytes including  
2.5 neutrophils, eosinophils and basophils, mast cells, megakaryocytes,  
platelets and dendritic  
cells, and lymphoid cells include T and B lymphocytes  
, thymic dendritic cells and natural  
killer (NK) cells. Hernopoietic stimulation, as used herein, refers to  
the increase in  
hemopoietic cell numbers or. . .

0); for eosinophils 0-700 per 1d ]mean - 150); for  
macrophages and monocytes 200-950 per 1tl (mean -430); for  
lymphocytes 1500-4000 per [LI  
(mean -2500); for erythrocytes 4.2 x 10<sup>6</sup> - 6.1 X 10<sup>6</sup> per 1tl; and for  
platelets 13 :). . .

at between 500 and 1000 per RI and  
severe neutropenia at below 500 per [d. Likewise, in adults, a  
lymphocyte count at less than  
1500 is considered a medically undesirable condition. In children, the  
value is less than  
3000. Other preselected values. . .

used interchangeably. An example of an  
immunocompromised subject is one infected with HIV and experiencing  
AIDS-related  
symptoms such as low CD4+ T lymphocyte levels. In still other  
embodiments, the methods  
may be used in subjects who are HIV-positive and who may be  
immunocompromised,  
provided that. . .

Thus in certain embodiments, the subjects are not myeloid or  
lymphoid suppressed or  
are not candidates for treatment with an agent which causes such  
suppression at the time of

treatment with the methods. . . in myeloid cells such as erythrocytes, neutrophils or platelets, to below protective or normal levels. Exemplary myelosuppressed conditions are  
hernopoietic malignancies, including leukemia and lymphoma and diseases such as chronic idiopathic neutropenia, cyclic neutropenia, anemia and thrombocytopenia. Similarly, lymphoid suppressing conditions are those which induce a reduction in lymphoid cells such as T lymphocytes. Suppression of lymphoid cells or some myeloid cells such as granulocytes is also referred to as immunosuppression since reduction in these cell types makes an individual susceptible to, inter alia, infection. Subjects may be exposed to myeloid, lymphoid or general immune suppressing conditions by the use of either immunosuppressant drugs such as cyclosporin or high dose chemotherapeutic compounds which.

iobenguane; lododoxorubicin; iporneanol, 4-; irinotecan; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide + estrogen + progesterone; leuprorelin; levarnisole; liarozole; linear polyarnine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; . . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.42	8.63

STN INTERNATIONAL LOGOFF AT 08:29:46 ON 21 MAR 2007